114 related articles for article (PubMed ID: 28341402)
1. Inhibitors of protein arginine deiminases and their efficacy in animal models of multiple sclerosis.
Sarswat A; Wasilewski E; Chakka SK; Bello AM; Caprariello AV; Muthuramu CM; Stys PK; Dunn SE; Kotra LP
Bioorg Med Chem; 2017 May; 25(9):2643-2656. PubMed ID: 28341402
[TBL] [Abstract][Full Text] [Related]
2. Noncovalent Protein Arginine Deiminase (PAD) Inhibitors Are Efficacious in Animal Models of Multiple Sclerosis.
Tejeda EJC; Bello AM; Wasilewski E; Koebel A; Dunn S; Kotra LP
J Med Chem; 2017 Nov; 60(21):8876-8887. PubMed ID: 29045782
[TBL] [Abstract][Full Text] [Related]
3. Novel inhibitors of protein arginine deiminase with potential activity in multiple sclerosis animal model.
Wei L; Wasilewski E; Chakka SK; Bello AM; Moscarello MA; Kotra LP
J Med Chem; 2013 Feb; 56(4):1715-22. PubMed ID: 23421315
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of peptidyl-arginine deiminases reverses protein-hypercitrullination and disease in mouse models of multiple sclerosis.
Moscarello MA; Lei H; Mastronardi FG; Winer S; Tsui H; Li Z; Ackerley C; Zhang L; Raijmakers R; Wood DD
Dis Model Mech; 2013 Mar; 6(2):467-78. PubMed ID: 23118341
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and biological evaluation of tetrazole analogs of Cl-amidine as protein arginine deiminase inhibitors.
Subramanian V; Knight JS; Parelkar S; Anguish L; Coonrod SA; Kaplan MJ; Thompson PR
J Med Chem; 2015 Feb; 58(3):1337-44. PubMed ID: 25559347
[TBL] [Abstract][Full Text] [Related]
6. Identification of multiple structurally distinct, nonpeptidic small molecule inhibitors of protein arginine deiminase 3 using a substrate-based fragment method.
Jamali H; Khan HA; Stringer JR; Chowdhury S; Ellman JA
J Am Chem Soc; 2015 Mar; 137(10):3616-21. PubMed ID: 25742366
[TBL] [Abstract][Full Text] [Related]
7. Discovery of 5-(2-chloro-4'-(1H-imidazol-1-yl)-[1,1'-biphenyl]-4-yl)-1H-tetrazole as potent and orally efficacious S-nitrosoglutathione reductase (GSNOR) inhibitors for the potential treatment of COPD.
Muthukaman N; Deshmukh S; Tondlekar S; Tambe M; Pisal D; Sarode N; Mhatre S; Chakraborti S; Shah D; Bhosale VM; Kulkarni A; Mahat MYA; Jadhav SB; Gudi GS; Khairatkar-Joshi N; Gharat LA
Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3766-3773. PubMed ID: 30340896
[TBL] [Abstract][Full Text] [Related]
8. Protein arginine deiminase 4 (PAD4): Current understanding and future therapeutic potential.
Jones JE; Causey CP; Knuckley B; Slack-Noyes JL; Thompson PR
Curr Opin Drug Discov Devel; 2009 Sep; 12(5):616-27. PubMed ID: 19736621
[TBL] [Abstract][Full Text] [Related]
9. Myelin Basic Protein Citrullination in Multiple Sclerosis: A Potential Therapeutic Target for the Pathology.
Yang L; Tan D; Piao H
Neurochem Res; 2016 Aug; 41(8):1845-56. PubMed ID: 27097548
[TBL] [Abstract][Full Text] [Related]
10. Development of a Selective Inhibitor of Protein Arginine Deiminase 2.
Muth A; Subramanian V; Beaumont E; Nagar M; Kerry P; McEwan P; Srinath H; Clancy K; Parelkar S; Thompson PR
J Med Chem; 2017 Apr; 60(7):3198-3211. PubMed ID: 28328217
[TBL] [Abstract][Full Text] [Related]
11. Sildenafil (Viagra®) down regulates cytokines and prevents demyelination in a cuprizone-induced MS mouse model.
Nunes AK; Rapôso C; Luna RL; Cruz-Höfling MA; Peixoto CA
Cytokine; 2012 Nov; 60(2):540-51. PubMed ID: 22749439
[TBL] [Abstract][Full Text] [Related]
12. Peptidyl Arginine Deiminases and Neurodegenerative Diseases.
Tu R; Grover HM; Kotra LP
Curr Med Chem; 2016; 23(2):104-14. PubMed ID: 26577926
[TBL] [Abstract][Full Text] [Related]
13. Abnormal morphology of myelin and axon pathology in murine models of multiple sclerosis.
Bando Y; Nomura T; Bochimoto H; Murakami K; Tanaka T; Watanabe T; Yoshida S
Neurochem Int; 2015 Feb; 81():16-27. PubMed ID: 25595039
[TBL] [Abstract][Full Text] [Related]
14. Involvement of AMPK, IKβα-NFκB and eNOS in the sildenafil anti-inflammatory mechanism in a demyelination model.
Nunes AK; Rapôso C; Rocha SW; Barbosa KP; Luna RL; da Cruz-Höfling MA; Peixoto CA
Brain Res; 2015 Nov; 1627():119-33. PubMed ID: 26404052
[TBL] [Abstract][Full Text] [Related]
15. Peptidylarginine deiminase expression and activity in PAD2 knock-out and PAD4-low mice.
van Beers JJ; Zendman AJ; Raijmakers R; Stammen-Vogelzangs J; Pruijn GJ
Biochimie; 2013 Feb; 95(2):299-308. PubMed ID: 23026755
[TBL] [Abstract][Full Text] [Related]
16. Restoration of FcRgamma/Fyn signaling repairs central nervous system demyelination.
Seiwa C; Yamamoto M; Tanaka K; Fukutake M; Ueki T; Takeda S; Sakai R; Ishige A; Watanabe K; Akita M; Yagi T; Tanaka K; Asou H
J Neurosci Res; 2007 Apr; 85(5):954-66. PubMed ID: 17290413
[TBL] [Abstract][Full Text] [Related]
17. Regional regulation of glutamate signaling during cuprizone-induced demyelination in the brain.
Azami Tameh A; Clarner T; Beyer C; Atlasi MA; Hassanzadeh G; Naderian H
Ann Anat; 2013 Oct; 195(5):415-23. PubMed ID: 23711509
[TBL] [Abstract][Full Text] [Related]
18. Deimination of the myelin basic protein decelerates its proteasome-mediated metabolism.
Kuzina ES; Kudriaeva AA; Glagoleva IS; Knorre VD; Gabibov AG; Belogurov AA
Dokl Biochem Biophys; 2016 Jul; 469(1):277-80. PubMed ID: 27599511
[TBL] [Abstract][Full Text] [Related]
19. Protein arginine deiminase 2 binds calcium in an ordered fashion: implications for inhibitor design.
Slade DJ; Fang P; Dreyton CJ; Zhang Y; Fuhrmann J; Rempel D; Bax BD; Coonrod SA; Lewis HD; Guo M; Gross ML; Thompson PR
ACS Chem Biol; 2015 Apr; 10(4):1043-53. PubMed ID: 25621824
[TBL] [Abstract][Full Text] [Related]
20. Peptidomimetics as protein arginine deiminase 4 (PAD4) inhibitors.
Trabocchi A; Pala N; Krimmelbein I; Menchi G; Guarna A; Sechi M; Dreker T; Scozzafava A; Supuran CT; Carta F
J Enzyme Inhib Med Chem; 2015 Jun; 30(3):466-71. PubMed ID: 25198885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
